Assertio Holdings Files Preliminary Recommendation for Zydus Acquisition at $23.50/Share Cash
ASRT has more than doubled off its 52-week low of $8.61.
Summary
Assertio Holdings filed a preliminary recommendation statement for its acquisition by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer, superseding a previous agreement.
Key Events · M&A and Partnerships · ASRT
-
Definitive Acquisition Agreement
Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC.
-
All-Cash Tender Offer
Zydus will acquire all outstanding shares of Assertio common stock for $23.50 per share in cash through a tender offer.
-
Board Recommendation
This Schedule 14D-9 filing serves as a preliminary communication regarding the board's recommendation for the proposed acquisition.
-
Supersedes Previous Deal
This acquisition by Zydus at $23.50 per share supersedes the prior amended merger agreement with Garda Therapeutics for $21.00 per share.
Analysis · ASRT · Life Sciences
This filing is a preliminary Solicitation/Recommendation Statement related to the definitive agreement for Zydus Worldwide DMCC to acquire Assertio Holdings. It confirms the all-cash offer of $23.50 per share, which represents a significant premium over the prior acquisition agreement with Garda Therapeutics and is slightly above the current trading price. This formal communication is a critical step in the tender offer process, signaling the board's support for the acquisition.
At the time of this filing, ASRT was trading at $23.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.7M. The 52-week trading range was $8.61 to $22.59. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.